Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody

BACKGROUND: Ideally, monoclonal antibodies provide selective treatment by targeting the tumour, without affecting normal tissues. Therefore, antibody imaging is of interest, preferably in early stages of drug development. However, the imaging signal consists of specific, as well as non-specific, upt...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:EJNMMI Res
Asıl Yazarlar: Jauw, Yvonne W. S., Huisman, Marc C., Nayak, Tapan K., Vugts, Danielle J., Christen, Randolph, Naegelen, Valerie Meresse, Ruettinger, Dominik, Heil, Florian, Lammertsma, Adriaan A., Verheul, Henk M. W., Hoekstra, Otto S., van Dongen, Guus A. M. S., Menke-van der Houven van Oordt, C. Willemien
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Berlin Heidelberg 2018
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5778091/
https://ncbi.nlm.nih.gov/pubmed/29356983
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13550-018-0358-8
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller